Figure 5.

IGF-1 and 15-PDGFH inhibitor treatment can partially prevent microgravity effect

(A) Principal-component analysis of transcriptome in 7 days in microgravity (MG) or gravity control conditions in the presence of drug treatment (IGF-1 or 15-PDGH-i) in biomimetic skeletal muscle samples.

(B) The 4-way Venn diagram shows the number of differentially expressed genes that were upregulated in microgravity, compared to gravity conditions, or whose differential expression could be either prevented by IGF-1 or 15-PDGH-i treatment (gray) or not prevented by drug treatment (IGF-1 in blue and 15-PDGH-i in orange).

(C) 4-way Venn diagram showing the number of differentially expressed genes downregulated in microgravity, compared to gravity conditions, or whose differential expression could be either prevented by IGF-1 or 15-PDGH-i treatment (gray) or not prevented by drug treatment (IGF-1 in blue and 15-PDGH-i in orange).

(D) Heatmap showing genes implicated in lipid biosynthesis, metabolic pathways, and adipogenesis.

(E) Heatmap showing genes implicated in cell adhesion, Notch signaling, and Wnt signaling (n = 2 donors per group).